Amilar Pharmaceuticals

Amilar Pharmaceuticals is a biotechnology company pioneering a novel therapeutic modality for the degradation of extracellular proteins. The company's proprietary ATAC (ASGPR-Targeted Antibodies for Degradation) platform utilizes the asialoglycoprotein receptor (ASGPR), a liver-specific scavenger receptor, to shuttle harmful proteins from the circulation into liver cells for lysosomal degradation. This approach aims to treat a broad range of diseases driven by pathogenic extracellular proteins, including metabolic, inflammatory, and cardiovascular conditions. Founded by OrbiMed and launched with significant Series A funding, Amilar is focused on expanding the reach of protein degradation beyond the intracellular space. The company is headquartered in Farmington, Connecticut, and continues to advance its pipeline of ATAC therapeutics toward clinical development.